IQVIA (NYSE:IQV) Insider Eric Sherbet Sells 4,446 Shares of Stock

IQVIA Holdings Inc. (NYSE:IQV) insider Eric Sherbet sold 4,446 shares of IQVIA stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $278.83, for a total value of $1,239,678.18. Following the transaction, the insider owned 24,989 shares of the company’s stock, valued at $6,967,682.87. The trade was a 15.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

IQVIA Stock Performance

Shares of IQV stock traded down $3.42 on Thursday, hitting $271.11. The company had a trading volume of 1,041,118 shares, compared to its average volume of 1,427,896. The firm has a market cap of $44.68 billion, a P/E ratio of 23.71, a price-to-earnings-growth ratio of 2.44 and a beta of 1.16. The company has a 50-day moving average price of $267.67 and a 200-day moving average price of $211.75. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a twelve month low of $154.50 and a twelve month high of $284.50.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, topping the consensus estimate of $3.26 by $0.08. The firm had revenue of $4.43 billion for the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. IQVIA’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same period last year, the company earned $3.00 earnings per share. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 11.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IQVIA

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Pension & Wealth Management Advisors Inc. acquired a new stake in shares of IQVIA in the third quarter valued at about $30,000. Compass Financial Management LLC purchased a new position in IQVIA in the 2nd quarter valued at about $27,000. Ascentis Independent Advisors acquired a new stake in IQVIA in the 1st quarter worth about $25,000. Elevation Wealth Partners LLC increased its stake in IQVIA by 218.8% during the 2nd quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company’s stock worth $30,000 after buying an additional 105 shares in the last quarter. Finally, Balance Wealth Partners LLC acquired a new position in shares of IQVIA during the third quarter valued at approximately $43,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on IQV. BMO Capital Markets raised their price objective on shares of IQVIA from $270.00 to $305.00 in a research note on Monday, October 19th. Barclays boosted their target price on shares of IQVIA from $275.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Rothschild & Co Redburn increased their price target on shares of IQVIA from $284.00 to $287.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. TD Cowen raised their price target on shares of IQVIA from $288.00 to $307.00 and gave the company a “buy” rating in a research report on Thursday, October 29th. Finally, Jefferies Financial Group raised their price target on shares of IQVIA from $220.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $294.21.

IQVIA Company Profile

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.